Ofira Zloto1,2, Tamara Wygnanski-Jaffe1,2, Sonal K Farzavandi3,4, Rosario Gomez-de-Liaño5, Derek T Sprunger6, Eedy Mezer7,8. 1. Goldschleger Eye Institute, Sheba Medical Center, Ramat Gan, Israel. 2. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. 3. Singapore National Eye Centre, Singapore, Singapore. 4. Duke-National University of Singapore Graduate Medical School, Singapore, Singapore. 5. Hospital Clínico/Instituto Castroviejo-Universidad Complutense Madrid, Madrid, Spain. 6. Department of Ophthalmology, Pediatric and Strabismus Section, Indiana University School of Medicine, Indianapolis, IN, USA. 7. Department of Ophthalmology, Ruth Rappaport Children's Hospital, Rambam Health Care campus, POB 9907, 3109901, Haifa, Israel. emezer@gmail.com. 8. Bruce Rappaport Faculty of Medicine, Technion, Israel Institute of Technology, I.I.T, Haifa, Israel. emezer@gmail.com.
Abstract
PURPOSE: To explore what the current worldwide preferred practice patterns of pediatric ophthalmologists are to decrease myopia progression among their patients. METHODS: A questionnaire was sent to all members of supranational and national pediatric ophthalmology and strabismus societies. RESULTS: The questionnaire was fully completed by most respondents 90.10% (847 of 940 responses). Fifty-seven percent (457) routinely treat to decrease myopia progression. The most common parameter to initiate treatment was a myopic increase of 1 diopter/year or more (74.8%, 246). Seventy percent (345) prescribed eye drops. Atropine 0.01% was the most popular (63.4%, 277) followed by atropine 1% (10.9%, 48) and atropine 0.5% (8.9%, 39). Eighty-six percent (394) of the respondents advised to spend more time outdoors, to reduce the amount of time viewing screens (60.2%, 277), and cutback the use of smart phones (63.9%, 294). CONCLUSIONS: Most pediatric ophthalmologists treat to decrease myopia. They employ a wide variety of means to decrease myopia progression. Atropine 0.01% is the most popular and safe modality used similarly to recent reports. However, there is no consensus when treatment should be initiated. Further prospective studies are needed to elucidate the best timing to start treatment and the applicability of recent studies in the Asian population to other ethnic groups. This will improve the ability to update pediatric ophthalmologist with evidenced-based treatment options to counter the myopia epidemic.
PURPOSE: To explore what the current worldwide preferred practice patterns of pediatric ophthalmologists are to decrease myopia progression among their patients. METHODS: A questionnaire was sent to all members of supranational and national pediatric ophthalmology and strabismus societies. RESULTS: The questionnaire was fully completed by most respondents 90.10% (847 of 940 responses). Fifty-seven percent (457) routinely treat to decrease myopia progression. The most common parameter to initiate treatment was a myopic increase of 1 diopter/year or more (74.8%, 246). Seventy percent (345) prescribed eye drops. Atropine 0.01% was the most popular (63.4%, 277) followed by atropine 1% (10.9%, 48) and atropine 0.5% (8.9%, 39). Eighty-six percent (394) of the respondents advised to spend more time outdoors, to reduce the amount of time viewing screens (60.2%, 277), and cutback the use of smart phones (63.9%, 294). CONCLUSIONS: Most pediatric ophthalmologists treat to decrease myopia. They employ a wide variety of means to decrease myopia progression. Atropine 0.01% is the most popular and safe modality used similarly to recent reports. However, there is no consensus when treatment should be initiated. Further prospective studies are needed to elucidate the best timing to start treatment and the applicability of recent studies in the Asian population to other ethnic groups. This will improve the ability to update pediatric ophthalmologist with evidenced-based treatment options to counter the myopia epidemic.
Authors: Kai Guo; Da Yong Yang; Yan Wang; Xian Rong Yang; Xin Xia Jing; Yuan Yuan Guo; Dan Zhu; Qi Sheng You; Yong Tao; Jost B Jonas Journal: Invest Ophthalmol Vis Sci Date: 2015-01-27 Impact factor: 4.799
Authors: Brien A Holden; Timothy R Fricke; David A Wilson; Monica Jong; Kovin S Naidoo; Padmaja Sankaridurg; Tien Y Wong; Thomas J Naduvilath; Serge Resnikoff Journal: Ophthalmology Date: 2016-02-11 Impact factor: 12.079